Published on 20 Feb 2024 on GuruFocus.com via Yahoo Finance
Halozyme Therapeutics Inc (HALO) Reports Strong Year-Over-Year Growth in Q4 and Full Year 2023 ...
Revenue Growth: Q4 revenue increased by 27% YOY to $230 million; full year 2023 revenue up 26% YOY to $829 million.Earnings Per Share: GAAP Diluted EPS at $0.65 for Q4 and $2.10 for full year; Non-GAAP Diluted EPS at $0.82 for Q4 and $2.77 for full year.Share Repurchase Program: Announced a new $750 million share repurchase program, signaling confidence in future growth.2024 Financial Guidance: Reiterates total revenue of $915-985 million, adjusted EBITDA of $535-585 million, and non-GAAP diluted EPS of $3.55-3.90.Strategic Partnerships and Approvals: Multiple product approvals and positive phase 3 data readouts, along with new global collaborations, position HALO for continued revenue growth.
Warning! GuruFocus has detected 3 Warning Signs with HALO.
On February 20, 2024, Halozyme Therapeutics Inc (NASDAQ:HALO) released its 8-K filing, detailing the financial and operating results for the fourth quarter and full year ended December 31, 2023. The company, a leader in developing novel oncology therapies, has reported significant year-over-year growth, underpinned by increased royalty revenue, product sales, and milestone revenue.